Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Myriad Genetics has taken over Rules-Based Medicine (RBM), a discoverer of novel biomarkers for pharmaceutical and biotechnology companies, for $80m.
Subscribe to our email newsletter
RBM’s protein detection platform offers pharmaceutical companies with critical information for accelerating drug development research and improve clinical trial outcomes.
The company’s proprietary Multi Analyte Profiling (MAP) technology offers pre-clinical and clinical researchers broad, cost-effective protein analyses in multiple species from a small sample volume.
With this acquisition, RBM will become the wholly subsidiary of Myriad, under the name Myriad RBM.
RBM will perform companion diagnostic discovery and development in collaboration with its pharmaceutical partners in addition to research projects for internal development.